Poloamer 188 as an Adjunct in Prolonged Hypotensive Resucitation
Technical Report,01 Jul 2006,30 Jun 2007
The University of Texas Health Science Center at Houston Houston United States
Pagination or Media Count:
Despite tremendous efforts, exsanguinations remains a leading cause of deaths approximately 40 in both civilian and military trauma. A subset of injured soldiers develop decompensated shock that requires early interventions if they are to survive. This project is testing the ability of a new drug, purified poloxamer 188 P188, to increase survival and reduce inflammation and organ injury resulting from prolonged periods of hypotensive resuscitation in a model specified by the ARMY. The results are strongly positive. Addition of P188 to standard therapy with Hextend significantly improved survival p0.002and reduced fluid requirements p0.0002 in rats subjected to prolonged hypotensive resuscitation. These studies are being followed up with studies with more complex injuries and with uncontrolled hemorrhage in rats, rabbits and pigs.
- Medicine and Medical Research